Department of General Surgery, Shanxi Provincial People's Hospital, Taiyuan, PR, China.
Pancreas Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key Laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, People's Republic of China.
World J Surg Oncol. 2024 Oct 28;22(1):284. doi: 10.1186/s12957-024-03524-0.
This study aims to elucidate the significance of the preoperative fibrinogen to pre-albumin ratio (FPR) in predicting the prognosis of pancreatic ductal adenocarcinoma (PDAC), a correlation not extensively explored previously.
A cohort of 563 patients diagnosed with PDAC and subjected to radical surgical resection was examined. We meticulously documented a range of inflammatory markers, clinical-pathological features, and oncological outcomes. The prognostic value of preoperative FPR was assessed using Kaplan-Meier survival analysis and Cox proportional hazards regression modeling. Furthermore, the predictive accuracy of FPR was evaluated through time-dependent receiver operating characteristic (ROC) curves and decision curve analyses (DCA).
The determined optimal threshold for FPR was 14.77, which facilitated the stratification of patients into groups with low and high FPR levels. Notably, patients in the high FPR cohort exhibited significantly reduced recurrence-free survival (RFS) and overall survival (OS) rates compared to their low FPR counterparts. Multivariate Cox regression analysis underscored FPR as an independent prognostic indicator for both RFS and OS. In comparison to the neutrophil-to-lymphocyte ratio (NLR), FPR demonstrated superior prognostic accuracy and clinical utility.
The preoperative fibrinogen to pre-albumin ratio serves as an independent prognostic marker for RFS and OS among PDAC patients undergoing radical resection. Our findings suggest that FPR could be a valuable addition to the current prognostic models, potentially guiding therapeutic decision-making and patient management strategies in PDAC.
本研究旨在阐明术前纤维蛋白原与前白蛋白比值(FPR)在预测胰腺导管腺癌(PDAC)预后中的意义,这一相关性此前并未广泛探讨。
对 563 例接受根治性手术切除的 PDAC 患者进行了检查。我们详细记录了一系列炎症标志物、临床病理特征和肿瘤学结局。采用 Kaplan-Meier 生存分析和 Cox 比例风险回归模型评估术前 FPR 的预后价值。此外,通过时间依赖性接收者操作特征(ROC)曲线和决策曲线分析(DCA)评估 FPR 的预测准确性。
确定 FPR 的最佳阈值为 14.77,这有助于将患者分为低 FPR 和高 FPR 组。值得注意的是,高 FPR 组患者的无复发生存率(RFS)和总生存率(OS)明显低于低 FPR 组患者。多变量 Cox 回归分析强调 FPR 是 RFS 和 OS 的独立预后指标。与中性粒细胞与淋巴细胞比值(NLR)相比,FPR 具有更高的预后准确性和临床实用性。
在接受根治性手术切除的 PDAC 患者中,术前纤维蛋白原与前白蛋白比值是 RFS 和 OS 的独立预后标志物。我们的研究结果表明,FPR 可能是目前预后模型的一个有价值的补充,可能指导 PDAC 的治疗决策和患者管理策略。